Solange Peters

Solange Peters

Medical Oncologist

Тhoracic oncology

CHUV | Lausanne University Hospital

Location Switzerland, Lausanne

Linkedin

X

Prof. Solange Peters is Full Professor, Chair of Thoracic Oncology, and Head of Medical Oncology (Cheffe de Service) at the University Hospital of Lausanne (CHUV), Switzerland, where she leads one of Europe’s premier thoracic oncology programs. An internationally recognized authority in lung cancer, Solange Peters served as President of the European Society for Medical Oncology (ESMO) from 2020 to 2022 and currently holds the title of ESMO Past President. She is President of the International Cancer Foundation (ICF) and the Swiss Academy of Multidisciplinary Oncology (SAMO), and serves as Scientific Coordinator and Scientific Committee Chair of the European Thoracic Oncology Platform (ETOP/IBCSG Partners), through which she holds funding co-responsibilities for clinical trial grants exceeding 100 million CHF per year. Solange Peters has been the lead or co-PI of numerous landmark international phase III trials in non-small cell lung cancer, mesothelioma, and thymic malignancies, including PEARLS/KEYNOTE-091, MERMAID-1, MERMAID-2, ALEX, CheckMate 743, MYSTIC, SKYSCAPER-1, ZEAL-1, and IPSOS. She serves as Associate Editor of the Annals of Oncology and Deputy Editor of Lung Cancer, and has authored more than 400 peer-reviewed publications with an H-index of 65. She holds an MD-PhD from the University of Lausanne.

Current Positions

  • Full Professor, Chair of Thoracic Oncology, and Head of Medical Oncology (Cheffe de Service), Department of Oncology, University Hospital of Lausanne (CHUV), Switzerland
  • Past President, European Society for Medical Oncology (ESMO), 2023–2025
  • President, International Cancer Foundation (ICF), 2021–present
  • President, Swiss Academy of Multidisciplinary Oncology (SAMO), 2022–present
  • Scientific Coordinator / Scientific Committee Chair, ETOP (European Thoracic Oncology Platform) and ETOP/IBCSG Partners, 2021–present
  • Vice-President, Swiss Cancer League, 2023–present
  • Foundation Council Member, ETOP, 2016–present
  • Chair, Scientific Committee, Fondazione San Salvatore, 2023–present
  • President, Scientific Advisory Board, Paris Saclay Cancer Cluster Association, 2023–present
  • Board Member, Galenica SA, 2023–present
  • Associate Editor, Annals of Oncology, 2020–present
  • Deputy Editor, Lung Cancer, 2023–present
  • Publication Committee Member, IASLC (International Association for the Study of Lung Cancer), 2014–present

Education

  • Medical School, University of Lausanne, 1992–1998
  • Exchange, University of Bari, Italy, 1995–1996
  • Federal Diploma of Medicine (MD), University of Lausanne, 1998
  • Molecular Biology Certificate, Faculty of Science, University of Lausanne, 1997
  • Molecular Virology Certificate, University of Lausanne, 1997
  • MD-PhD, University of Lausanne (thesis: HIV drug resistance), 2002

Postgraduate Training

  • Residency, Internal Medicine, University Hospital of Lausanne (CHUV), 2002–2005
  • Fellowship, Multidisciplinary Oncology Center, University Hospital of Lausanne, 2005
  • ESMO Examination in Oncology, 2006 (renewed 2012, 2017; MORA recertification 2017, 2022)
  • Senior Physician (“Médecin Associé”), University Hospital of Lausanne, 2009
  • Privat Docent and Maître d’Enseignement et Recherche (PD-MER1), University of Lausanne, 2013
  • Chief Resident in charge of thoracic malignancies, Oncology Department, CHUV, 2009–2015

Research Activity

  • Adjuvant and perioperative immunotherapy in NSCLC: Solange Peters served as international co-chair/PI of PEARLS/KEYNOTE-091 (MSD-sponsored, with ETOP and EORTC), a landmark phase III study of adjuvant pembrolizumab vs. placebo in resected NSCLC; co-chair/PI of MERMAID-1 (durvalumab plus chemotherapy in completely resected stage II–III NSCLC) and MERMAID-2 (durvalumab in stage II–III NSCLC)
  • First-line immunotherapy combinations in advanced NSCLC: PI of MYSTIC (phase III; durvalumab ± tremelimumab vs. chemotherapy in first-line NSCLC); SKYSCAPER-1 (tiragolumab plus atezolizumab vs. placebo plus atezolizumab in PD-L1-selected NSCLC); ZEAL-1 (niraparib plus pembrolizumab maintenance in advanced/metastatic NSCLC); IPSOS (atezolizumab vs. single-agent chemotherapy in platinum-ineligible advanced NSCLC)
  • ALK-positive NSCLC: Co-PI of the ALEX trial (alectinib vs. crizotinib in treatment-naive ALK-positive advanced NSCLC), a practice-changing phase III study
  • Mesothelioma: International PI of CheckMate 743 (nivolumab plus ipilimumab vs. chemotherapy as first-line therapy in unresectable pleural mesothelioma) and BEAT Mesothelioma (chemotherapy, immunotherapy, and bevacizumab)
  • Thymic malignancies: Co-PI of NIVOTHYM (immunotherapy for thymic carcinoma)
  • Locally advanced NSCLC: PI of NICOLAS (nivolumab consolidation after chemoradiotherapy in stage IIIA/B NSCLC); SAKK 16/08 (preoperative chemoradiotherapy plus cetuximab in stage IIIB NSCLC)
  • EGFR/HER2-targeted therapies: Co-PI of BOOSTER (osimertinib/bevacizumab in EGFR-positive NSCLC) and NICHE (afatinib in HER2-mutant NSCLC)
  • Biomarker and genomic programs: PI of SPECTALung (EORTC/ETOP biomarker screening program for thoracic tumors); LUNGSCAPE (ETOP molecular profiling project); B-FAST (multiple targeted therapies as treatments for NSCLC using blood-based biomarkers); EMPHASIS (erlotinib MALDI-TOF phase III signature in squamous cell NSCLC)
  • Bone-directed therapy in NSCLC: Co-PI of SPLENDOUR (denosumab in lung cancer, ETOP/EORTC) and RANK signaling research (Swiss Cancer Research grant 2015–2017)
  • Tumor immunology and immune microenvironment: PI of Swiss Cancer Research grant characterizing sugar usage by pro-tumor neutrophils in lung cancer (2020–2022); co-PI on Oncosuisse grant on intravital microscopy and tumor vasculature/immune cell infiltration in malignant mesothelioma (2020–2023)
  • Small cell lung cancer: PI of STIMULI (ipilimumab in limited-disease SCLC, ETOP)
  • Photodynamic therapy for pleural malignancies: Co-PI on Swiss National Science Foundation grants on photo-induction to improve cisplatin delivery and low-dose photodynamic therapy for pleural tumors
  • Global oncology: Oncosuisse grant on oncology in resource-limited countries (2019–present)
  • Cancer communication and training: Oncosuisse grants on communication training outcomes in cancer care (2017–2019)

Honors and Awards

  • President, European Society for Medical Oncology (ESMO), 2020–2022
  • Scientific Chair, ESMO Annual Meeting (30,000 delegates), ESMO Asia, ESMO Immunotherapy Congress, 2020–2022
  • Scientific Chair, ESMO Congress 2018
  • Scientific Chair, ELCC 2016
  • President, International Cancer Foundation (ICF), 2021–present
  • President, Swiss Academy of Multidisciplinary Oncology (SAMO), 2022–present
  • Proposed President, Swiss Cancer League, 2025 or 2027
  • President, Scientific Advisory Board, Paris Saclay Cancer Cluster Association, 2023–present
  • Chair, Scientific Committee, Fondazione San Salvatore, 2023–present
  • Board Member, Galenica SA, 2023–present
  • Gateway Award (with Rising Tide Foundation) — CATATeM Phase IB/II Study, 2014
  • Award, Dr. Arnold U. und Susanne Huggenberger-Bischoff Stiftung zur Krebsforschung — ALK biology/RT-PCR, 2012

Memberships and Affiliations

  • European Society for Medical Oncology (ESMO) — Past President; former Executive Board of Directors Member; former ESMO Clinical Guidelines Editor/Chair for Thoracic Malignancies (2013–2019); former Women for Oncology Task Force/Committee Chair (2014–2020); Faculty Member (2012–present)
  • International Association for the Study of Lung Cancer (IASLC) — Publication Committee Member (2014–present); former Elected Board of Directors Member (2013–2017)
  • European Thoracic Oncology Platform (ETOP/IBCSG Partners) — Scientific Coordinator/Scientific Committee Chair; Foundation Council Member; Chair, Information and Communication Committee
  • Swiss Academy of Multidisciplinary Oncology (SAMO) — President (2022–present); former Vice-President and Board Member
  • Swiss Cancer League — Vice-President (2023–present); Board Member (2017–present)
  • International Cancer Foundation (ICF) — President (2021–present)
  • Fondazione San Salvatore — Chair, Scientific Committee (2023–present)
  • Scientific Advisory Council Member: AbbVie, Amgen, Arcus, AstraZeneca, BMS, Roche/Genentech, MSD, Novartis, Pfizer, Takeda, GSK, Daiichi Sankyo, and numerous others
  • Reviewer: New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Thorax, Chest, European Respiratory
  • Journal, European Journal of Cancer, Lung Cancer

Areas of Specialization

  • Non-small cell lung cancer — all stages and histologies
  • Immunotherapy in thoracic malignancies
  • Targeted therapy in NSCLC — ALK, EGFR, HER2, KRAS
  • Adjuvant and perioperative systemic therapy
  • Malignant pleural mesothelioma
  • Thymic malignancies
  • Small cell lung cancer
  • Biomarker-driven clinical trial design
  • Thoracic oncology clinical guidelines development
  • Cancer communication and medical education

Selected Publications

Peters S, Cho BC, Luft AV, Alatorre-Alexander J, Geater SL, Laktionov K, et al. “Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: five-year overall survival outcomes from the phase 3 POSEIDON trial.” Journal of Thoracic Oncology 20(1):76–93, 2025.

Peters S, Paz-Ares LG, Reck M, Carbone DP, Brahmer JR, Borghaei H, et al. “Long-term survival outcomes with first-line nivolumab plus ipilimumab-based treatment in patients with metastatic NSCLC and tumor PD-L1 lower than 1%: a pooled analysis.” Journal of Thoracic Oncology 20(1):94–108, 2025.

Meyer ML, BG Fitzgerald, Paz-Ares L, Cappuzzo F, Jaenne PA, Peters S, et al. “New promises and challenges in the treatment of advanced non-small-cell lung cancer.” The Lancet 404(10454):803–822, 2024.

Passaro A, Al Bakir M, Hamilton EG, Diehn M, André F, Roy-Chowdhuri S, Peters S, et al. “Cancer biomarkers: Emerging trends and clinical implications for personalized treatment.” Cell 187(7):1617–1635, 2024.

Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Galan-Cobo A, Le JT, Peters S, et al. “CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.” Nature 635(8038):462–471, 2024.

Budczies J, Kazdal D, Menzel M, Beck S, Kluck K, Altbuerger C, Peters S, et al. “Tumour mutational burden: clinical utility, challenges and emerging improvements.” Nature Reviews Clinical Oncology 21(10):725–742, 2024.

Paz-Ares L, Borghaei H, Liu SV, Peters S, Herbst RS, Stencel K, Majem M, et al. “Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte).” The Lancet 405(10495):2129–2143, 2025.

Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, et al. “Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.” Nature Medicine 28(9):1831–1839, 2022.

O’Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Peters S, et al. “Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091).” The Lancet Oncology 23(10):1274–1286, 2022.

Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, et al. “First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.” Annals of Oncology 33(5):488–499, 2022.

Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, Peters S, et al. “Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.” Annals of Oncology 34(4):339–357, 2023.

Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, Peters S, et al. “Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.” Annals of Oncology 34(4):358–376, 2023.

Passaro A, Jänne PA, Peters S. “Antibody-drug conjugates in lung cancer: recent advances and implementing strategies.” Journal of Clinical Oncology 41(21):3747–3761, 2023.

De Langen AJ, Johnson ML, Mazieres J, Dingemans AMC, Mountzios G, Peters S, et al. “Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.” The Lancet 401(10378):733–746, 2023.

Gungabeesoon J, Gort-Freitas NA, Kiss M, Bolli E, Messemaker M, Peters S, et al. “A neutrophil response linked to tumor control in immunotherapy.” Cell 186(7):1448–1464, 2023.

Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Peters S, et al. “Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.” Annals of Oncology 33(12):1217–1238, 2022.

Passaro A, Jänne PA, Mok T, Peters S. “Overcoming therapy resistance in EGFR-mutant lung cancer.” Nature Cancer 2(4):377–391, 2021.

Passaro A, Brahmer J, Antonia S, Mok T, Peters S. “Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies.” Journal of Clinical Oncology 40(6):598–610, 2022.

Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Álvarez R, et al. “Progression-free and overall survival for concurrent nivolumab with standard concurrent chemoradiotherapy in locally advanced stage IIIA-B NSCLC: results from the NICOLAS trial.” Journal of Thoracic Oncology 16(2):278–288, 2021.

Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. “First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.” The Lancet 397(10272):375–386, 2021.

Remon J, Soria JC, Peters S. “Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines.” Annals of Oncology 32(12):1637–1642, 2021.

Lee SM, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B, Peters S, et al. “First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for platinum-containing regimen (IPSOS).” The Lancet 402(10400):451–463, 2023.

Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Peters S, et al. “Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non–small-cell lung cancer: the phase III POSEIDON study.” Journal of Clinical Oncology 41(6):1213–1227, 2023.

Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, Peters S, et al. “Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized clinical trial.” JAMA Oncology 6(5):661–674, 2020.

Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, et al. “Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study.” Journal of Clinical Oncology 38(21):2369–2379, 2020.

Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, Peters S, et al. “Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.” Annals of Oncology 31(8):1056–1064, 2020.

Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, Peters S, et al. “COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.” The Lancet Oncology 21(7):914–922, 2020.

Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Peters S, et al. “Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.” The Lancet 395(10241):1907–1918, 2020.

Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, et al. “Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1–selected advanced non–small-cell lung cancer (BIRCH).” Journal of Clinical Oncology 35(24):2781–2789, 2017.

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SHI, et al. “Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer.” New England Journal of Medicine 377(9):829–838, 2017.

Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, Pérol M, Wrona A, et al. “Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.” Annals of Oncology 29(11):2214–2222, 2018.

Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, et al. “Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non–small cell lung cancer in the ALEX study.” Journal of Thoracic Oncology 14(7):1233–1243, 2019.

Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K, et al. “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.” Annals of Oncology 28:iv119–iv142, 2017.

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Peters S, et al. “Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.” Nature Reviews Clinical Oncology 16(9):563–580, 2019.

Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S, et al. “Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.” Annals of Oncology 30(1):44–56, 2019.

Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Peters S, et al. “Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.” Annals of Oncology 28:iv1–iv21, 2017.

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Peters S, et al. “Nivolumab plus ipilimumab in advanced non–small-cell lung cancer.” New England Journal of Medicine 381(21):2020–2031, 2019.

Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, Peters S, et al. “First-line nivolumab in stage IV or recurrent non–small-cell lung cancer.” New England Journal of Medicine 376(25):2415–2426, 2017.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Peters S, et al. “Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.” Annals of Oncology 29:iv192–iv237, 2018.

Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, Peters S, et al. “EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours.” Annals of Oncology 32(11):1332–1347, 2021.

Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, et al. “Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.” The Lancet Oncology 21(5):645–654, 2020.

Dingemans AMC, Früh M, Ardizzoni A, Besse B, Faivre-Finn C, Peters S, et al. “Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.” Annals of Oncology 32(7):839–853, 2021.

Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Peters S, et al. “ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.” Annals of Oncology 33(5):466–487, 2022.

Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Peters S, et al. “SAKK 16/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non–small-cell lung cancer.” Journal of Clinical Oncology 39(26):2872–2880, 2021.

Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, Majem M, et al. “A randomised phase III study evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: the ETOP/EORTC SPLENDOUR trial.” Journal of Thoracic Oncology 15(10):1647–1656, 2020.

Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, et al. “Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451.” Journal of Clinical Oncology 39(12):1349–1359, 2021.

Peters S, Pujol JL, Dafni U, Dómine M, Popat S, Reck M, Andrade J, et al. “Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy — results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.” Annals of Oncology 33(1):67–79, 2022.

Wagner AD, Oertelt-Prigione S, Adjei A, Buclin T, Cristina V, Csajka C, Peters S, et al. “Gender medicine and oncology: report and consensus of an ESMO workshop.” Annals of Oncology 30(12):1914–1924, 2019.

Passaro A, Mok TS, Peters S, Popat S, Ahn MJ, De Marinis F. “Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations.” Journal of Thoracic Oncology 16(5):764–773, 2021.

Peters S, Zimmermann S, Adjei AA. “Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug–drug interactions.” Cancer Treatment Reviews 40(8):917–926, 2014.

Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, et al. “Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives.” Journal of Clinical Oncology 31(16):1997–2003, 2013.

Peters S, Adjei AA. “MET: a promising anticancer therapeutic target.” Nature Reviews Clinical Oncology 9(6):314–326, 2012.

Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E, et al. “Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.” Annals of Oncology 23:vii56–vii64, 2012.

Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, Gerard MA, Peters S, et al. “Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.” The Lancet 386(9998):1049–1056, 2015.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, et al. “Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF).” The Lancet Respiratory Medicine 5(5):435–444, 2017.

Dziadziuszko R, Smit EF, Dafni U, Wolf J, Wasąg B, Biernat W, Finn SP, Peters S, et al. “Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP).” Journal of Thoracic Oncology 14(6):1086–1094, 2019.

Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O’Brien M, Pope A, Peters S, et al. “A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma (PROMISE-meso).” Annals of Oncology 31(12):1734–1745, 2020.

Peters S, Stahel RA, Dafni U, Aix SP, Massutí B, Gautschi O, Coate L, et al. “Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non–small cell lung cancer failing first-line platinum-based doublet chemotherapy.” Journal of Thoracic Oncology 12(4):752–762, 2017.

Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E, et al. “Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.” Annals of Oncology 24:vi99–vi105, 2013.

Peters S, Michielin O, Zimmermann S. “Dramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated Lung Adenocarcinoma.” Journal of Clinical Oncology 31(20):e341–e344, 2013.

Peters S, Bexelius C, Munk V, Leighl N. “The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer.” Cancer Treatment Reviews 45:139–162, 2016.

All information is sourced from publicly available materials.